EGFR signaling and autophagy dependence for growth, survival, and therapy resistance
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
The epidermal growth factor receptor (EGFR) is amplified or mutated in various human epithelial tumors. Its expression and activation leads to cell proliferation, differentiation, and survival. Consistently, EGFR amplification or expression of EGFR variant 3 (EGFRvIII) is associated with resistance to conventional cancer therapy through activation of pro-survival signaling and DNA-repair mechanisms. EGFR targeting has successfully been exploited as strategy to increase treatment efficacy. Nevertheless, these targeting strategies have only been proven effective in a limited percentage of human tumors. Recent knowledge indicates that EGFR deregulated tumors display differences in autophagy and dependence on autophagy for growth and survival and the use of autophagy to increase resistance to EGFR-targeting drugs. In this review the dependency on autophagy and its role in mediating resistance to EGFR-targeting agents will be discussed. Considering the current knowledge, autophagy inhibition could provide a novel strategy to enhance therapy efficacy in treatment of EGFR deregulated tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mitochondrial Autophagy Is an HIF-1-dependent Adaptive Metabolic Response to Hypoxia
Zhang, H., Bosch-Marce, M., Shimoda, L. A., Tan, Y. S., Baek, J. H., Wesley, J. B., Gonzalez, F. J., & Semenza, G. L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800102200 · Cited by 1,601
RetractedAMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Kim, J., Kundu, M., Viollet, B., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2152 · Cited by 7,227 · cited 2×
“46 Cell Cycle volume 13 issue 1 by phosphorylating ULK1 Ser757 and disrupting the interaction between ULK1 and 5′ AMP-activated protein kinase (AMPK), thereby preventing ULK1 to initiate an autophagy activating complex with FIP200 and ATG13.(70,71) During periods of starvation, mTOR dissociates from the ULK1 complex,…”
BackgroundUntangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 1×
“In many different cancer cell types, the ErbB pathway becomes hyperactivated by a range of mechanisms, including overproduction of ligands, overproduction of receptors, or constitutive activation of receptors.(2) In general, EGFR signaling is triggered by ligand binding to the extracellular ligand binding domain.”
BackgroundErlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Induction of autophagy and inhibition of tumorigenesis by beclin 1
Liang, X. H., Jackson, S., Seaman, M., Brown, K., Kempkes, B., Hibshoosh, H., & Levine, B. (1999) · Nature · doi:10.1038/45257 · Cited by 3,347
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170 · cited 4×
“For instance, in NSCLC the incidence of EGFR mutations among clinical responders to gefitinib or erlotinib is 77%, compared with only 7% in NSCLC cases that are refractory to tyrosine kinase inhibitor (TKI) treatment.(20) Multiple studies have shown differences in treatment outcome associated with EGFR mutations.”
BackgroundResultInfluentialThe role of autophagy during the early neonatal starvation period
Kuma, A., Hatano, M., Matsui, M., Yamamoto, A., Nakaya, H., Yoshimori, T., Ohsumi, Y., Tokuhisa, T., & Mizushima, N. (2004) · Nature · doi:10.1038/nature03029 · Cited by 2,865
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., & Waterfield, M. D. (1984) · Nature · doi:10.1038/307521a0 · Cited by 2,516
Impairment of starvation-induced and constitutive autophagy in Atg7 -deficient mice
Komatsu, M., Waguri, S., Ueno, T., Iwata, J., Murata, S., Tanida, I., Ezaki, J., Mizushima, N., Ohsumi, Y., Uchiyama, Y., et al. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200412022 · Cited by 2,331
Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene
Qu, X., Yu, J., Bhagat, G., Furuya, N., Hibshoosh, H., Troxel, A., Rosen, J., Eskelinen, E.-L., Mizushima, N., Ohsumi, Y., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci20039 · Cited by 2,311
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 2×
“This T790M mutation is considered an acquired mutation and converts TKIsensitive tumors into (reversible) TKI-resistant tumors.(21) Like the T790M mutation, other exon 20 mutated proteins are resistant to clinically achievable doses of reversible (gefitinib, erlotinib) and irreversible (neratinib, afatinib, PF00299804…”
BackgroundYue, Z., Jin, S., Yang, C., Levine, A. J., & Heintz, N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2436255100 · Cited by 2,116
Nutrient-dependent mTORC1 Association with the ULK1–Atg13–FIP200 Complex Required for Autophagy
Hosokawa, N., Hara, T., Kaizuka, T., Kishi, C., Takamura, A., Miura, Y., Iemura, S.-I., Natsume, T., Takehana, K., Yamada, N., et al. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-12-1248 · Cited by 2,076 · cited 1×
“During periods of starvation, mTOR dissociates from the ULK1 complex, leading to less ULK1 phosphorylation, and increases ULK1 kinase activity.(72,73) Recently, a role for ULK1 activation for survival of hypoxic cells was identified.”
BackgroundZhong, Z., Wen, Z., & Darnell, J. E. (1994) · Science · doi:10.1126/science.8140422 · Cited by 2,070
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Bellot, G., Garcia-Medina, R., Gounon, P., Chiche, J., Roux, D., Pouysségur, J., & Mazure, N. M. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00166-09 · Cited by 1,501
Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks
Alers, S., Löffler, A. S., Wesselborg, S., & Stork, B. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06159-11 · Cited by 1,483 · cited 2×
“46 Cell Cycle volume 13 issue 1 by phosphorylating ULK1 Ser757 and disrupting the interaction between ULK1 and 5′ AMP-activated protein kinase (AMPK), thereby preventing ULK1 to initiate an autophagy activating complex with FIP200 and ATG13.(70,71) During periods of starvation, mTOR dissociates from the ULK1 complex,…”
BackgroundActivated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
Guo, J. Y., Chen, H.-Y., Mathew, R., Fan, J., Strohecker, A. M., Karsli-Uzunbas, G., Kamphorst, J. J., Chen, G., Lemons, J. M. S., Karantza, V., et al. (2011) · Genes & Development · doi:10.1101/gad.2016311 · Cited by 1,323 · cited 2×
“Several studies have implicated RAS activity in the induction of autophagy, as displayed by a high autophagic flux after oncogenic RAS transformation.(77) Increased autophagy in these cells is required to sustain a high metabolic rate, to prevent accumulation of damaged mitochondria, reduce oxygen consumption, and to…”
BackgroundMatsunaga, K., Saitoh, T., Tabata, K., Omori, H., Satoh, T., Kurotori, N., Maejima, I., Shirahama-Noda, K., Ichimura, T., Isobe, T., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1846 · Cited by 1,235 · cited 1×
“Beclin 1 is a coiled-coil protein involved in the regulation of autophagy in mammalian cells and is a component of the class III phosphatidylinositol-3-kinase (PI3K) complex.(90) Beclin 1 promotes autophagy, and cells with reduced Beclin 1 expression exhibit reduced autophagic activity.”
BackgroundBeclin 1 Forms Two Distinct Phosphatidylinositol 3-Kinase Complexes with Mammalian Atg14 and UVRAG
Itakura, E., Kishi, C., Inoue, K., & Mizushima, N. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-01-0080 · Cited by 1,176 · cited 2×
“Beclin 1 may also promote survival as an interacting partner of an anti-apoptotic protein Bcl-2.(96) Binding of Bcl-2 to Beclin 1 inhibits Beclin 1-dependent autophagy and Beclin 1-dependent autophagic cell death.”
BackgroundInfluentialNordsmark, M., Bentzen, S. M., Rudat, V., Brizel, D., Lartigau, E., Stadler, P., Becker, A., Adam, M., Molls, M., Dunst, J., et al. (2005) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2005.06.038 · Cited by 953
Rouschop, K. M. A., van den Beucken, T., Dubois, L., Niessen, H., Bussink, J., Savelkouls, K., Keulers, T., Mujcic, H., Landuyt, W., Voncken, J. W., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40027 · Cited by 829
Self-citationWeinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805 · cited 1×
“For a number of different oncogenes, data supporting addiction in tumors have been gathered.(11,12) For EGFR in particular, positive results in clinical trials with different antagonists have been considered as clinical evidence of oncogene addiction, *Correspondence to: Barry Jutten; Email: b.”
BackgroundYasuda, H., Kobayashi, S., & Costa, D. B. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70129-2 · Cited by 610 · cited 3×
“Like the T790M mutation, other exon 20 mutated proteins are resistant to clinically achievable doses of reversible (gefitinib, erlotinib) and irreversible (neratinib, afatinib, PF00299804) TKIs in preclinical models.(22) Growing clinical experience with tumors harboring EGFR exon 20 insertions correspond with the prec…”
BackgroundInfluentialSugawa, N., Ekstrand, A. J., James, C. D., & Collins, V. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.21.8602 · Cited by 594
Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation
Lock, R., Roy, S., Kenific, C. M., Su, J. S., Salas, E., Ronen, S. M., & Debnath, J. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-06-0500 · Cited by 467
Overgaard, J. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.03.004 · Cited by 456
Hypoxia signals autophagy in tumor cells via AMPK activity, independent of HIF-1, BNIP3, and BNIP3L
Papandreou, I., Lim, A. L., Laderoute, K., & Denko, N. C. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.84 · Cited by 334
Tai, W.-T., Shiau, C.-W., Chen, H.-L., Liu, C.-Y., Lin, C.-S., Cheng, A.-L., Chen, P.-J., & Chen, K.-F. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.18 · Cited by 202
Signaling of Mitochondrial Biogenesis following Oxidant Injury
Rasbach, K. A., & Schnellmann, R. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608009200 · Cited by 168
Cited by
Levy, J. M. M., Towers, C. G., & Thorburn, A. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.53 · Cited by 2,526
Autophagy in cancer: moving from understanding mechanism to improving therapy responses in patients
Mulcahy Levy, J. M., & Thorburn, A. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0474-7 · Cited by 416
A Kinase-Independent Role for EGF Receptor in Autophagy Initiation
Tan, X., Thapa, N., Sun, Y., & Anderson, R. A. (2015) · Cell · doi:10.1016/j.cell.2014.12.006 · Cited by 223
ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation
Wu, Y., Zhang, C., Liu, X., He, Z., Shan, B., Zeng, Q., Zhao, Q., Zhu, H., Liao, H., Cen, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22467-8 · Cited by 117
Koustas, E., Karamouzis, M. V., Mihailidou, C., Schizas, D., & Papavassiliou, A. G. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.023 · Cited by 79
Metadata
- Authors
- Jutten, B., & rouschop, K.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2013-12-13
- Volume
- 13
- Issue
- 1
- Pages
- 42-51
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- OpenAlex
- W2106426363
- Cited by
- 121
- References
- 33
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.